LAMEA Facial Injectable Market Size, Share & Industry Trends Analysis Report By End-use (MedSpa, Dermatology Clinics and Hospitals), By Product, By Application, By Country and Growth Forecast, 2023 - 2029

The Latin America, Middle East and Africa Facial Injectable Market should witness market growth of 16.5% CAGR during the forecast period (2023-2029).

The most common procedures use fillers because the risk involved in this type of treatment is quite low. In addition, because fillers like hyaluronic acid and poly-L lactic acid are readily accepted by the body, there can be few allergic responses. In comparison to invasive surgeries, minimally invasive procedures include benefits like shorter hospital stays, smaller incisions, quick outpatient services, quick wound healing, less pain, and a lower chance of complications. As a result, over the projection period, there will likely be a rise in demand for facial injectables.

Cosmetic-grade HA has a low molecular weight that enables deep epidermal penetration of the substance, aiding in water retention in the cells and releasing antioxidants that slow the aging process. In addition to acting as a moisturizer, HA treats burns, skin ulcers, and wounds. In plastic surgery, HA is also applied to the lips as a filler. The increased usage of HA in cosmetic products or as a dermal filler is predicted to support market expansion.

A wide variety of ethnic groups make up the population of the United Arab Emirates (UAE). The UAE is thought to have the third-highest number of patients in the Middle East seeking cosmetic surgery, behind Saudi Arabia and Egypt. Dubai has been identified as the medical aesthetics hub of the Middle East, boasting 276 facilities, 386 board-certified dermatologists, and 236 certified cosmetic surgeons. The demand for cosmetic procedures in the UAE has been increasing as cosmetic surgery ranks among the top five medical tourism treatments. The aesthetics industry is one of the key factors influencing medical tourism to the UAE. Both a significant increase in regional patients and a surge in regionally based, globally qualified businesses may be responsible for this. Due to this, many aesthetic procedures are carried out in the region, which assists in the expansion of the regional market.

The Brazil market dominated the LAMEA Facial Injectable Market by Country in 2022 thereby, achieving a market value of $490.2 Million by 2029. The Argentina market is experiencing a CAGR of 17.1% during (2023-2029). Additionally, The UAE market would exhibit a CAGR of 16.2% during (2023-2029).

Based on End-use, the market is segmented into MedSpa, Dermatology Clinics and Hospitals. Based on Product, the market is segmented into Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Poly-L-Lactic Acid (PLLA), Collagen & PMMA Microspheres, Hyaluronic Acid (HA) and Others. Based on Application, the market is segmented into Facial Line Correction, Face Lift, Lip Augmentation, Acne Scar Treatment, Lipoatrophy Treatment and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Suneva Medical, Inc., Medytox Inc., Sinclair Pharma Ltd., Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group), Anika Therapeutics, Inc., Prollenium Medical Technologies Inc., Galderma S.A., and Allergan PLC (AbbVie, Inc.).

Scope of the Study

By End-use

• MedSpa
• Dermatology Clinics
• Hospitals

By Product

• Botulinum Toxin Type A
• Calcium Hydroxylapatite (CaHA)
• Poly-L-Lactic Acid (PLLA)
• Collagen & PMMA Microspheres
• Hyaluronic Acid (HA)
• Others

By Application

• Facial Line Correction
• Face Lift
• Lip Augmentation
• Acne Scar Treatment
• Lipoatrophy Treatment
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Ipsen Pharma Biotech SAS
• Merz Pharma GmbH & Co. KGaA
• Suneva Medical, Inc.
• Medytox Inc.
• Sinclair Pharma Ltd.
• Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group)
• Anika Therapeutics, Inc.
• Prollenium Medical Technologies Inc.
• Galderma S.A.
• Allergan PLC (AbbVie, Inc.)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free